Nouscom

Basel, Switzerland

Nouscom is a biotech company that develops a series of immunotherapies that are capable of selectively killing tumor cells.

$7.6M raised

Mar 2024

Series C

Top Investors

BpifranceVersant Ventures5AM VenturesPanakes PartnersEQT Life Sciences

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Nouscom raised?

Nouscom has raised $7.6M in total funding. The most recent round was Series C. The last funding was announced in March 2024.

Who are Nouscom's investors?

Nouscom's investors include Bpifrance, Versant Ventures, 5AM Ventures, Panakes Partners, EQT Life Sciences.

Where is Nouscom headquartered?

Nouscom is headquartered in Basel, Switzerland.

What does Nouscom do?

Nouscom is a biotech company that develops a series of immunotherapies that are capable of selectively killing tumor cells.

What stage is Nouscom at?

Nouscom is at the Series C stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated March 21, 2024.

MLA

"Nouscom — Funding & Investors." VCBacked, March 21, 2024, https://www.vcbacked.co/company/nouscom. Accessed June 7, 2026.

APA

VCBacked. (2024). Nouscom — Funding & Investors. Retrieved June 7, 2026, from https://www.vcbacked.co/company/nouscom

Wikipedia (cite web)

{{cite web |title=Nouscom — Funding & Investors |url=https://www.vcbacked.co/company/nouscom |website=VCBacked |access-date=June 7, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated March 21, 2024.